Modernizing Pharmacovigilance: Leveraging AI, Automation, and Real-World Data for Drug Safety.

Notice

This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.

Year : 2026 | Volume : 15 | 01 | Page :
    By

    Yash Prakash Rathod,

  • Pranav Dattatray Farate,

  • Dilan Philip Kurian,

  • Ashlesha Shripad Mandale,

  • Himalay Prassan Shende,

  • Priya Shekhar Daingade,

  • Vaishali Ganesh Mundhe,

  • Dr. Tushar Treembak Shelke,

  1. Student, Department of Pharmacy, Genba Sopanrao Moze College of Pharmacy, Pune, India
  2. Student, Department of Pharmacy, Genba Sopanrao Moze College of Pharmacy, Pune, India
  3. Student, Department of Pharmacy, Genba Sopanrao Moze College of Pharmacy, Pune, India
  4. Student, Department of Pharmacy, Genba Sopanrao Moze College of Pharmacy, Pune, India
  5. Student, Department of Pharmacy, Genba Sopanrao Moze College of Pharmacy, Pune, India
  6. Assistant Professor, Department of Pharmacy, Genba Sopanrao Moze College of Pharmacy, Pune, India
  7. Assistant Professor, Department of Pharmacy, Genba Sopanrao Moze College of Pharmacy,, Pune, India
  8. Principal, Department of Pharmacy, Genba Sopanrao Moze College of Pharmacy, Wagholi, Pune, India

Abstract

Pharmacovigilance, or PV, is the pharmacological science relating to the detection, assessment, understanding and prevention of adverse effects, mainly long term and short-term adverse effects of medicines specific objectives are to: increase patient care and safety when using medications and all medical and paramedical
therapies; assist in evaluating the benefits, drawbacks, efficacy, and risks of medications, ensuring their safe, prudent, and more effective use; and promote clinical training, education, and pharmacovigilance, as well as its successful public dissemination. Pharmacovigilance (PV) is the main and most important component of clinical
research that aims to lower the risk of drug-related accidents for patients. The aim of this article is to give a brief overview regarding the value of the practice of PV to determine and maintain the rational use of medications in the field of pharmacotherapy. Pharmacovigilance (PV) is crucial for public health, mainly for
monitoring and assessing adverse drug reactions to ensure patient health. Artificial intelligence (AI) integration is transforming PV by enabling massive data analysis, automating processes, and enhancing the detection of safety signals. This increased capability results in the implementation of more extensive and proactive risk
management. An essential sunshade of medication safety, pharmacovigilance (PV) guarantees smooth and efficient drug relation, clinical practice, and public health initiatives around the world by monitoring and evaluating the adverse drug reactions (ADRs). PV provides solutions to major drug safety issues which may
affect public health across borders. Although many PV centres around the world are now monitoring drug safety, the start of the millennium presented major challenges to enhance drug safety and surveillance. This article discusses drug safety, the function and limitation of global PV centres, and future PV thinking in
healthcare. The pharmaceutical industry concentrates on case management, signal detection, and benefit-risk management. These are essential for post-marketing surveillance, product safety, and appropriate medical use through risk management.

Keywords: Adverse Drug Reaction (ADR), Artificial Intelligence (AI), Biomarkers, Genomic Study, Pharmacovigilance, Wearable Devices.

How to cite this article:
Yash Prakash Rathod, Pranav Dattatray Farate, Dilan Philip Kurian, Ashlesha Shripad Mandale, Himalay Prassan Shende, Priya Shekhar Daingade, Vaishali Ganesh Mundhe, Dr. Tushar Treembak Shelke. Modernizing Pharmacovigilance: Leveraging AI, Automation, and Real-World Data for Drug Safety.. Research and Reviews : Journal of Computational Biology. 2026; 15(01):-.
How to cite this URL:
Yash Prakash Rathod, Pranav Dattatray Farate, Dilan Philip Kurian, Ashlesha Shripad Mandale, Himalay Prassan Shende, Priya Shekhar Daingade, Vaishali Ganesh Mundhe, Dr. Tushar Treembak Shelke. Modernizing Pharmacovigilance: Leveraging AI, Automation, and Real-World Data for Drug Safety.. Research and Reviews : Journal of Computational Biology. 2026; 15(01):-. Available from: https://journals.stmjournals.com/rrjocb/article=2026/view=236748


References

1. Dol HS, SHINDE VR, VIJAYKUMAR MALI J, NAVNATH KHAKAL N. Pharmacovigilance: A practical approach for reshaping patient safety. Innovare J Med Sci [Internet]. 2017 Mar. 1 [cited 2025 Jun. 11];5(2):1-4.
2. Kumar DA, Reddenna L, Basha SA. Pharmacovigilance programme of India. INNOVATIONS in pharmacy. 2015 Jan 1;6(1).
3. Ahire YS, Patil JH, Chordiya HN, Deore RA, Bairagi VA. Advanced applications of artificial intelligence in pharmacovigilance: Current trends and future perspectives. J Pharm Res. 2024 Jan;23(1):23-33
4. Jeetu G, Anusha G. Pharmacovigilance: a worldwide master key for drug safety monitoring. Journal of Young Pharmacists. 2010 Jul 1;2(3):315-20.
5. Schmider J, Kumar K, LaForest C, Swankoski B, Naim K, Caubel PM. Innovation in pharmacovigilance: use of artificial intelligence in adverse event case processing. Clinical pharmacology & therapeutics. 2019 Apr;105(4):954-61.
6. Sumit K, Ashish B. Pharmacovigilance in India: perspectives and prospects. J Drug Deliv and Ther. 2013;3(4):237-46.
7. Vishwakarma, Rohit & Rai, Vishal & Singh, Shekhar. (2024). A review paper on Pharmacovigilance: An Overview. 4. 60-70.

8. Ghosh R, Kempf D, Pufko A, Barrios Martinez LF, Davis CM, Sethi S. Automation opportunities in pharmacovigilance: an industry survey. Pharmaceutical Medicine. 2020 Feb; 34:7-18.
9. Hans M, Gupta SK. Comparative evaluation of pharmacovigilance regulation of the United States, United Kingdom, Canada, India and the need for global harmonized practices. Perspectives in clinical research. 2018 Oct 1;9(4):170-4.
10. Kompa B, Hakim JB, Palepu A, Kompa KG, Smith M, Bain PA, Woloszynek S, Painter JL, Bate A, Beam AL. Artificial intelligence based on machine learning in pharmacovigilance: a scoping review. Drug Safety. 2022 May;45(5):477-91.
11. Murali K, Kaur S, Prakash A, Medhi B. Artificial intelligence in pharmacovigilance: practical utility. Indian Journal of Pharmacology. 2019 Nov 1;51(6):373-6.
12. Desai MK. Artificial intelligence in pharmacovigilance–Opportunities and challenges. Perspectives in Clinical Research. 2024 Jul 1;15(3):116-21.
13. Dimitsaki S, Natsiavas P, Jaulent MC. Applying AI to Structured Real-World Data for Pharmacovigilance Purposes: Scoping Review. Journal of Medical Internet Research. 2024 Dec 30;26:e57824.
14. Baby A. Leveraging Artificial Intelligence in Pharmacovigilance: Enhancing Drug Safety Through Data- Driven Approaches.
15. Shukla D, Bhatt S, Gupta D, Verma S. Role of Artifical Intelligence in Pharmacovigilance. Journal of Drug Discovery and Health Sciences. 2024 Dec 30;1(04):230-8.
16. Choi YH, Han CY, Kim KS, Kim SG. Future directions of pharmacovigilance studies using electronic medical recording and human genetic databases. Toxicological Research. 2019 Oct;35:319-30.
17. McCorvey A, Hale C. Advancing personalized medicine: Has genomic testing enhanced pharmacovigilance to improve drug efficacy?. Journal of Interprofessional Education & Practice. 2017 Jun 1;7:65-71.
18. Moride Y, Haramburu F, Requejo AA, Begaud B. Under-reporting of adverse drug reactions in general practice. British journal of clinical pharmacology. 1997 Feb;43(2):177-81.
19. Tandon VR, Mahajan V, Khajuria V, Gillani Z. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India. Indian journal of pharmacology. 2015 Jan 1;47(1):65-71.
20. Costa C, Abeijon P, Rodrigues DA, Figueiras A, Herdeiro MT, Torre C. Factors associated with underreporting of adverse drug reactions by patients: a systematic review. International Journal of Clinical Pharmacy. 2023 Dec;45(6):1349-58.
21. Grampp G, Felix T. Pharmacovigilance considerations for biosimilars in the USA. BioDrugs. 2015 Oct;29:309-21.
22. Garcia-Gancedo L, Bate A. Digital biomarkers for post-licensure safety monitoring. Drug Discovery Today.2022 Nov 1;27(11):103354.

23. Farid, Farhad & Ferdouszzaman, Md & Khan, Tania & Sharma, Debobrata. (2025). Advances in molecular biomarkers for pharmacovigilance: Early detection of drug toxicity. World Journal of Biology Pharmacy and Health Sciences. 21. 71-081. 10.30574/wjbphs.2025.21.2.0142.
24. Liu F, Jagannatha A, Yu H. Towards drug safety surveillance and pharmacovigilance: current progress in detecting medication and adverse drug events from electronic health records. Drug safety. 2019 Jan 21;42(1):95-7.
25. Segura-Bedmar I, Martínez P. Pharmacovigilance through the development of text mining and natural language processing techniques. Journal of biomedical informatics. 2015 Dec 1;58:288-91.
26. Zakari N, Al-Razgan M, Alsaadi A, Alshareef H, Alotaibi S. Blockchain technology in the pharmaceutical industry: a systematic.
27. Shruti Aher, Manoj Mahajan, Aman Upaganlawar, Chandrashekhar Upasani, Pharmacovigilance In The Digital Age, Int. J. of Pharm. Sci., 2024, Vol 2, Issue 4, 691-711.
28. Anestina N, Obiageli C, Anthony O, Alade A, Mustapha A, Oluwaferanmi A. Ensuring Drug Safety: Comprehensive Pharmacovigilance Strategies for Public Health.
29. Singh A, Twomey K, Baker R. Global pharmacovigilance regulations: call for reharmonization. Clinical Trials. 2018 Dec;15(6):631-2.
30. Gettman, David. (2015). Proactive Pharmacovigilance: Leveraging Predictive Analytics and Wearable Health Tech to Manage Medication-Related Risks in High-Risk Patient Population.10.13140/RG.2.2.28342.20807.
31. Bahk CY, Goshgarian M, Donahue K, Freifeld CC, Menone CM, Pierce CE, Rodriguez H, Brownstein JS, Furberg R, Dasgupta N. Increasing patient engagement in pharmacovigilance through online community outreach and mobile reporting applications: an analysis of adverse event reporting for the Essure device in the US. Pharmaceutical medicine. 2015 Dec;29:331-40.
32. Silva L, Pacheco T, Araújo E, Duarte RJ, Ribeiro-Vaz I, Ferreira-da-Silva R. Unveiling the future: precision pharmacovigilance in the era of personalized medicine. International Journal of Clinical Pharmacy. 2024 Jun;46(3):755-60.
33. Getov I, Panayotova D, Dobrev S, Dimitrova M, Petkova V. Opportunities for implementing digital applications to monitor the impact of risk-minimization measures within the pharmacovigilance process: Scoping review of published literature. Pharmacia. 2025 Jan 9;72:1-6.
34. Yang J, Li F. The Impact of Technological Progress on Pharmacovigilance. Pharmacovigilance-Facts, Challenges, Limitations and Opportunities: Facts, Challenges, Limitations and Opportunities. 2025 Apr 30:43.

Ahead of Print Subscription Review Article
Volume 15
01
Received 12/09/2025
Accepted 07/02/2026
Published 12/02/2026
Publication Time 153 Days
100

Login


My IP

PlumX Metrics